ScandiDos AB (publ) (SDOS.ST)
SEK 1.27
(0.4%)
SEK 1.27
(0.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 47.55 Million SEK | -125.45% |
| 2022 | 52.94 Million SEK | 10.49% |
| 2021 | 47.92 Million SEK | -3.63% |
| 2020 | 49.72 Million SEK | 8.8% |
| 2019 | 45.7 Million SEK | 16.97% |
| 2018 | 39.07 Million SEK | 0.11% |
| 2017 | 39.03 Million SEK | 4.82% |
| 2016 | 37.23 Million SEK | 37.5% |
| 2015 | 27.08 Million SEK | -4.58% |
| 2014 | 28.38 Million SEK | -14.38% |
| 2013 | 33.14 Million SEK | 3.08% |
| 2012 | 32.15 Million SEK | 24.21% |
| 2011 | 25.88 Million SEK | 10.83% |
| 2010 | 23.36 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 9.95 Million SEK | 223.93% |
| 2023 Q1 | 8.95 Million SEK | -45.15% |
| 2023 FY | -13.47 Million SEK | -125.45% |
| 2023 Q4 | -7.83 Million SEK | -963.29% |
| 2023 Q3 | 907 Thousand SEK | -93.5% |
| 2023 Q2 | 13.95 Million SEK | 55.77% |
| 2022 Q4 | 16.33 Million SEK | 16.09% |
| 2022 Q1 | 9.41 Million SEK | -30.28% |
| 2022 FY | 52.94 Million SEK | 10.49% |
| 2022 Q2 | 13.12 Million SEK | 39.51% |
| 2022 Q3 | 14.07 Million SEK | 7.17% |
| 2021 Q2 | 11.44 Million SEK | 18.45% |
| 2021 Q4 | 13.49 Million SEK | 1.44% |
| 2021 FY | 47.92 Million SEK | -3.63% |
| 2021 Q1 | 9.66 Million SEK | -16.59% |
| 2021 Q3 | 13.3 Million SEK | 16.23% |
| 2020 Q3 | 12.55 Million SEK | -7.96% |
| 2020 Q4 | 11.58 Million SEK | -7.72% |
| 2020 FY | 49.72 Million SEK | 8.8% |
| 2020 Q1 | 12.1 Million SEK | 23.8% |
| 2020 Q2 | 13.64 Million SEK | 12.76% |
| 2019 Q4 | 9.77 Million SEK | -33.65% |
| 2019 Q3 | 14.73 Million SEK | 40.21% |
| 2019 FY | 45.7 Million SEK | 16.97% |
| 2019 Q1 | 10.69 Million SEK | -9.35% |
| 2019 Q2 | 10.5 Million SEK | -1.71% |
| 2018 Q3 | 13.44 Million SEK | 95.34% |
| 2018 Q4 | 11.79 Million SEK | -12.29% |
| 2018 FY | 39.07 Million SEK | 0.11% |
| 2018 Q2 | 6.88 Million SEK | -0.99% |
| 2018 Q1 | 6.95 Million SEK | -41.2% |
| 2017 Q4 | 11.82 Million SEK | 21.31% |
| 2017 FY | 39.03 Million SEK | 4.82% |
| 2017 Q1 | 8.03 Million SEK | -2.17% |
| 2017 Q2 | 8.85 Million SEK | 10.28% |
| 2017 Q3 | 9.74 Million SEK | 10.02% |
| 2016 Q1 | 7.12 Million SEK | 2.11% |
| 2016 FY | 37.23 Million SEK | 37.5% |
| 2016 Q4 | 8.21 Million SEK | -26.78% |
| 2016 Q3 | 11.21 Million SEK | 12.47% |
| 2016 Q2 | 9.97 Million SEK | 40.0% |
| 2015 Q1 | 2.98 Million SEK | -57.51% |
| 2015 Q4 | 6.97 Million SEK | -17.7% |
| 2015 Q2 | 8.5 Million SEK | 185.08% |
| 2015 Q3 | 8.47 Million SEK | -0.31% |
| 2015 FY | 27.08 Million SEK | -4.58% |
| 2014 FY | 28.38 Million SEK | -14.38% |
| 2014 Q4 | 7.01 Million SEK | -21.7% |
| 2014 Q2 | 7.64 Million SEK | 60.91% |
| 2014 Q1 | 4.75 Million SEK | -34.22% |
| 2014 Q3 | 8.96 Million SEK | 17.19% |
| 2013 Q4 | 7.22 Million SEK | -27.17% |
| 2013 FY | 33.14 Million SEK | 3.08% |
| 2013 Q1 | 7.46 Million SEK | -29.46% |
| 2013 Q2 | 8.53 Million SEK | 14.44% |
| 2013 Q3 | 9.92 Million SEK | 16.21% |
| 2012 Q4 | 10.57 Million SEK | 56.1% |
| 2012 Q3 | 6.77 Million SEK | 0.0% |
| 2012 FY | 32.15 Million SEK | 24.21% |
| 2011 FY | 25.88 Million SEK | 10.83% |
| 2010 FY | 23.36 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -797.772% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 84.18% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 84.18% |
| Arcoma AB | 11.07 Million SEK | -329.546% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 66.028% |
| BICO Group AB (publ) | 1.83 Billion SEK | 97.402% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 80.956% |
| CellaVision AB (publ) | 463.04 Million SEK | 89.73% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -1486.753% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 267.364% |
| C-Rad AB (publ) | 66.01 Million SEK | 27.963% |
| Duearity AB (publ) | -4.17 Million SEK | 1238.224% |
| Dignitana AB (publ) | 58.97 Million SEK | 19.359% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 213.768% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.646% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 194.698% |
| Iconovo AB (publ) | 17.57 Million SEK | -170.542% |
| Integrum AB (publ) | 690.56 Thousand SEK | -6786.42% |
| Luxbright AB (publ) | -2.79 Million SEK | 1800.29% |
| Mentice AB (publ) | 236.38 Million SEK | 79.882% |
| OssDsign AB (publ) | 83.64 Million SEK | 43.147% |
| Paxman AB (publ) | 12.61 Million SEK | -276.882% |
| Promimic AB (publ) | 38.51 Million SEK | -23.471% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 193.699% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -196.533% |
| Sectra AB (publ) | 557.55 Million SEK | 91.471% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 56.364% |
| Senzime AB (publ) | 8.33 Million SEK | -470.272% |
| SpectraCure AB (publ) | -9.22 Million SEK | 615.613% |
| Stille AB | 132.17 Million SEK | 64.02% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 97.596% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 88.594% |